IQVIA Holdings Inc. (NYSE:IQV) Position Cut by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 81.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,226 shares of the medical research company's stock after selling 5,416 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in IQVIA were worth $216,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in IQV. Brighton Jones LLC lifted its holdings in IQVIA by 244.4% during the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Blair William & Co. IL lifted its holdings in IQVIA by 42.0% during the fourth quarter. Blair William & Co. IL now owns 5,742 shares of the medical research company's stock valued at $1,128,000 after purchasing an additional 1,699 shares in the last quarter. Brown Brothers Harriman & Co. lifted its holdings in IQVIA by 468.3% during the fourth quarter. Brown Brothers Harriman & Co. now owns 466 shares of the medical research company's stock valued at $92,000 after purchasing an additional 384 shares in the last quarter. Schroder Investment Management Group lifted its holdings in IQVIA by 4.5% during the fourth quarter. Schroder Investment Management Group now owns 77,715 shares of the medical research company's stock valued at $15,272,000 after purchasing an additional 3,333 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in shares of IQVIA by 12.7% in the fourth quarter. Wellington Management Group LLP now owns 9,791 shares of the medical research company's stock worth $1,924,000 after buying an additional 1,106 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 5,800 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the sale, the insider owned 27,178 shares of the company's stock, valued at approximately $5,165,178.90. This represents a 17.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider directly owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on IQV. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price target for the stock from $260.00 to $160.00 in a research note on Friday, April 25th. Redburn Partners set a $188.00 target price on shares of IQVIA in a research note on Friday, May 23rd. Mizuho boosted their price target on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Cowen restated a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. Finally, Robert W. Baird lifted their price objective on shares of IQVIA from $159.00 to $196.00 and gave the company a "neutral" rating in a report on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Price Performance

Shares of NYSE:IQV traded down $3.42 on Friday, reaching $182.44. 1,644,130 shares of the company were exchanged, compared to its average volume of 2,321,248. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The firm has a market cap of $31.01 billion, a price-to-earnings ratio of 26.40, a price-to-earnings-growth ratio of 2.00 and a beta of 1.30. The company has a 50-day moving average of $162.11 and a 200-day moving average of $169.89.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The company's revenue was up 5.3% on a year-over-year basis. During the same period in the prior year, the firm posted $2.64 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.